Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Endometrial ablation; less is more? Historical cohort study comparing long-term outcomes from two time periods and two treatment modalities for 854 women.

Helleland L, Bergesen LF, Rinnan KJ, Engelsen IB, Hordnes K, Trovik J.

PLoS One. 2019 Jul 10;14(7):e0219294. doi: 10.1371/journal.pone.0219294. eCollection 2019.


Impact of night shifts on laparoscopic skills and cognitive function among gynecologists.

Veddeng A, Husby T, Engelsen IB, Kent A, Flaatten H.

Acta Obstet Gynecol Scand. 2014 Dec;93(12):1255-61. doi: 10.1111/aogs.12496. Epub 2014 Sep 30.


Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome.

Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Øyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB.

Br J Cancer. 2012 May 8;106(10):1682-8. doi: 10.1038/bjc.2012.91. Epub 2012 Mar 13.


Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting.

Wik E, Trovik J, Iversen OE, Engelsen IB, Stefansson IM, Vestrheim LC, Haugland HK, Akslen LA, Salvesen HB.

Am J Obstet Gynecol. 2009 Dec;201(6):603.e1-7. doi: 10.1016/j.ajog.2009.07.029. Epub 2009 Oct 3.


Biologic markers in endometrial cancer treatment.

Engelsen IB, Akslen LA, Salvesen HB.

APMIS. 2009 Oct;117(10):693-707. doi: 10.1111/j.1600-0463.2009.02467.x. Review.


Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.

Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4834-9. doi: 10.1073/pnas.0806514106. Epub 2009 Mar 4.


GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.

Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB.

Am J Obstet Gynecol. 2008 Nov;199(5):543.e1-7. doi: 10.1016/j.ajog.2008.04.043. Epub 2008 Jul 3.


Drug-sensitive FGFR2 mutations in endometrial carcinoma.

Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7. doi: 10.1073/pnas.0803379105. Epub 2008 Jun 13.


Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma.

Engelsen IB, Mannelqvist M, Stefansson IM, Carter SL, Beroukhim R, Øyan AM, Otte AP, Kalland KH, Akslen LA, Salvesen HB.

Br J Cancer. 2008 May 20;98(10):1662-9. doi: 10.1038/sj.bjc.6604360. Epub 2008 May 13.


HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.

Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB.

Int J Oncol. 2008 Feb;32(2):307-16.


Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.

Engelsen IB, Stefansson I, Akslen LA, Salvesen HB.

Am J Obstet Gynecol. 2006 Oct;195(4):979-86. Epub 2006 May 3.


Peripartum hysterectomy-incidence and maternal morbidity.

Engelsen IB, Albrechtsen S, Iversen OE.

Acta Obstet Gynecol Scand. 2001 May;80(5):409-12.


Supplemental Content

Loading ...
Support Center